TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03995563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Continous epidural injection will be done during 10 days. D group will be injected a 0.19% ropivacaine 8mL and dexametasone 1mg every other day during 10 days.~.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Continous epidural injection will be done during 10 days Both group will be injected a 0.19% ropivacaine 8mL every other day during 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Continous epidural injection will be done during 10 days Both group will be injected a 0.19% ropivacaine 8mL every other day during 10 days
Study: NCT03297632

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Functional resistance exercise
Description: Functional resistance program designed for older individuals with low muscle mass and muscle strength. The goal is to implement exercises that are possible for the participants to also perform in their home environment, through the use of basic equipment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional resistance exercise
Description: Functional resistance program designed for older individuals with low muscle mass and muscle strength. The goal is to implement exercises that are possible for the participants to also perform in their home environment, through the use of basic equipment.
Study: NCT01114724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Valiant Thoracic Stent Graft with the Captivia Delivery System
Description: All subjects will be implanted with this device
Study: NCT01943617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: anti-viral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: anti-viral therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin-α
Description: anti-viral and antitherapy
Study: NCT02988661

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Disease Self-Management Program (CDSMP)
Description: The CDSMP consist of 6 weekly classes of two and a half hours each one, for six weeks. A group of 10-16 people with different chronic conditions attend the classes together. Classes are facilitated by two certified leaders, one or both of whom are non-health professionals with chronic diseases. The workshop covers topics such as: 1) how to deal with frustration, fatigue, pain and isolation, 2) exercise for maintaining and improving strength, flexibility, and endurance, 3) communicating effectively with family, friends, and health professionals, 4) nutrition, 5) decision making, 6) appropriate use of medications and how to evaluate new treatments. Participants receive a companion book, Living a Healthy Life with Chronic Conditions, and an audio relaxation CD, Relaxation for Mind and Body.
Study: NCT00720135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DI-Leu16-IL2 immunocytokine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies
Study: NCT00864110

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)
Description: one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20 mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG will be injected

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Technetium 99m ethylenedicysteine-deoxyglucose
Description: 99mTc EC-DG injection, single dose, slow IV push over 3-5 minutes, yielding a target activity of 20 mCi (range 20-30 mCi)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 18 F fluorodeoxyglucose
Description: single injection of 18F FDG (range 10-20 mCi)
Study: NCT02404571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDP chemotherapy
Description: gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
Study: NCT03495518

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symptom feedback to Health Care Provider
Description: These children will complete SPARK daily for 5 days in a row, daily symptom reports will be printed and provided in the patient chart. On days 1 and 3, a report describing symptoms that are a lot or extremely bothersome will be emailed to the physician providing direct medical

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: A clinical research associate will visit the participant on days 1 and 5±1 and will obtain SSPedi scores on an iPad. Reports will not be printed or emailed to the physician.
Study: NCT03869099

Intervention type: OTHER
Intervention: Pneumonia Case Management Practices
Description: Standard practices of pneumonia case management at three levels of health care; community level, first level care facility and practitioner level, across Pakistan.

Intervention type: OTHER
Intervention: Pneumonia Case Management Practices
Description: Standard practices of pneumonia case management at three levels of health care; community level, first level care facility and practitioner level, across Pakistan.

Intervention type: OTHER
Intervention: Pneumonia Case Management Practices
Description: Standard practices of pneumonia case management at three levels of health care; community level, first level care facility and practitioner level, across Pakistan.

Intervention type: OTHER
Intervention: Pneumonia Case Management Practices
Description: Standard practices of pneumonia case management at three levels of health care; community level, first level care facility and practitioner level, across Pakistan.
Study: NCT02703766

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: overfeeding induced weight gain

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: overfeeding induced weight gain
Study: NCT00963508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Malathion gel 0.5%
Description: Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Permethrin 1% rinse (Nix Crème)
Description: Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head head lice are still present.
Study: NCT03571789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vine™
Description: The Vine™ is made of a super-elastic nitinol wire comprises a helix that resides within the CCA lumen and a linear stem that traverses the CCA wall. The helix includes three segments: supporting coils, filter, and leading coils.~The device is available in sizes of 6.0mm - 10.0mm (in 0.5mm intervals) to accommodate individual CCA diameters
Study: NCT01222299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bepotastine besilate nasal product - low dose
Description: sterile nasal product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bepotastine besilate nasal product - medium dose
Description: sterile nasal product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bepotastine besilate nasal product - high dose
Description: sterile nasal product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator nasal product
Description: sterile nasal product
Study: NCT02530541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHG
Description: Varied application times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHG
Description: Varied application times

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHG
Description: Varied application times
Study: NCT02754739

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Pravastatin)
Description: Pill manufactured to mimic pravastatin 40mg tablet once daily for 24 weeks and nutritional education by a nutritionist

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutritional education only
Description: Only nutritional education by a nutritionist
Study: NCT04147520

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Interview
Description: Single (60 min) session discussion of alcohol use and associated experiences.
Study: NCT03122132

Intervention type: DRUG
Intervention: ombitasvir/paritaprevir/ritonavir 8 weeks
Description: Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ ritonavir 8 weeks

Intervention type: DRUG
Intervention: dasabuvir 8 weeks
Description: Spanish cohort with HCV treated in real practice with dasabuvir 8 weeks
Study: NCT03976492

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnostic of specific biomarkers
Description: Protein and metabolic product differences will be detected from blood or lesion samples of normal population, patients with traumatic brain injury and/or non-brain injury using mass spectrometry proteomics and metabolomics analysis platform. Diagnostic markers of potential traumatic brain injury will be found, and their differential diagnostic values were discussed.

Intervention type: DIAGNOSTIC_TEST
Intervention: diagnostic of specific biomarkers
Description: Protein and metabolic product differences will be detected from blood or lesion samples of normal population, patients with traumatic brain injury and/or non-brain injury using mass spectrometry proteomics and metabolomics analysis platform. Diagnostic markers of potential traumatic brain injury will be found, and their differential diagnostic values were discussed.
Study: NCT02432508

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser acupuncture (Olympic)
Description: Physiolaser Olympic laser acupuncture device (50mW, 655nm)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Laser acupuncture (Olympic)
Description: Physiolaser Olympic laser acupuncture device (50mW, 655nm)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Laser acupuncture (Olympic)
Description: Physiolaser Olympic laser acupuncture device (Low dose of laser energy: 5mW, 655nm)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser acupuncture (Olympic)
Description: Physiolaser Olympic laser acupuncture device (Low dose of laser energy: 5mW, 655nm)
Study: NCT02907307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LactiSal vaginal gel 1%
Description: to be administered daily intravaginally for 6 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LactiSal vaginal tablet 50mg
Description: to be administered daily intravaginally for 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole vaginal tablet 100mg
Description: to be administered daily intravaginally for 6 days
Study: NCT02812693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04712695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Based Interventions
Description: Proprioception Training Interventions

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise Based Interventions
Description: Proprioception Training Interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Based Interventions
Description: Proprioception Training Interventions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Based Interventions
Description: Proprioception Training Interventions
Study: NCT04850872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAYwithHEART Programme for adolescent athletes
Description: PLAYwithHEART programme for adolescent athletes is an intervention programme based on Mindfulness, Acceptance, and Compassion for adolescent athletes
Study: NCT04389151

Intervention type: DRUG
Group type: OTHER
Intervention: Toripalimab
Description: Toripalimab union CAPEOX scheme： Toripalimab 240mg, ivgtt, Q3w Oxaliplatin 130mg/m2,ivgtt, Q3w capecitabine 1000mg/m2, p.o Q3w
Study: NCT01014208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OFATUMUMAB + DHAP
Description: 3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RITUXIMAB + DHAP
Description: 3 cycles of treatment will be administered. Each cycle will last 21 days. rituximab dose: cycle 1, day 1 - 375 mg/m2; cycle 1, day 8 - 375 mg/m2; cycle 2, day 1 and cycle 3, day 1 - 375 mg/m2. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
Study: NCT04019990

Intervention type: OTHER
Group type: OTHER
Intervention: The effect of throwers ten exercise programme on wheelchair basketball and ambulant basketball players
Description: Throwers Ten exercise programme is a programme designed to improve the power, strength and endurance of large muscle groups required for the throwing activity. It consists of exercises involving the movement of upper limb joints in full range of joint motion or at specified specific angles, with the help of a resistance band and weights specific to individual athletes. In the literature, no study has demonstrated the effectiveness of Throwers Ten exercise programme in wheelchair basketball and ambulant basketball players.
Study: NCT01994837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: Tablet
Study: NCT01169740

Intervention type: PROCEDURE
Intervention: Measurement of bilirubin in blood and skin color
Description: Blood sampling and analysis, measurement of skin color by transcutaneous bilirubinometry
Study: NCT01165853

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose
Description: 25% dose at 8-week intervention assigned to subjects.

Intervention type: OTHER
Group type: OTHER
Intervention: Fructose
Description: 25% dose at 8-week intervention assigned to subjects.
Study: NCT01290289

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidura, CSE & IV
Description: Gp 1: received CSE analgesia: 25µg of fentanyl \& a bolus dose of 10 ml of 0.5% lidocaine was injected epidurally. E top-ups of 5-10 ml of 0.5-0.8% lidocaine were then injected.~Gp 2: received CSE analgesia: 25µg of fentanyl \& a bolus dose of 10 ml of 0.0625% bupivacaine was injected epidurally. E top-ups of 5-10 ml of 0.0625-0.25% bupivacaine were then injected.~Gp 3: received 50µg of E fentanyl analgesia \& a bolus of 10 ml of 0.5% lidocaine was administered, followed by lidocaine E top-ups of 5-10 ml of 0.5-0.8%.~Gp 4: received analgesia: 50µg of E fentanyl \& a bolus dose of 10 ml of 0.125% bupivacaine was administered, followed by E bupivacaine top-ups of 5-10 ml of 0.125-0.25%.~Gp 5: 50mg of IV pethidine was administered as loading dose, followed by 0.5 mg/kg.
Study: NCT01985451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexe
Description: Patients with relapsed PCNSL patients were treated with high-dose pemetrexed (900mg/m²).
Study: NCT03265795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Poly Ether Ether Ketone PSI (patient specific implant).
Description: reconstruction of the bone and the original volume of maxillary sinus accurately (in terms of clinical and radiographic parameters).
Study: NCT03133013

Intervention type: DEVICE
Group type: OTHER
Intervention: SLEEPSCOPE
Description: Brainwave measurement device which is connected to the participant by an electrode attached to the forehead and another electrode behind one ear
Study: NCT01985451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients with relapsed PCNSL patients were treated with temozolomide (200mg/m² day 1-5,28).
Study: NCT03114839

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota (LcS)
Description: A fermented milk containing LcS, 65 ml for oral administration, 1 bottle per day for 7 days. One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; 0.9 g of protein; and at least 6.5 x 10\^9 colony-forming units of LcS.
Study: NCT03780218

Intervention type: OTHER
Intervention: Respiratory function
Description: Respiratory function test evaluates the participants' pulmonary function and respiratory muscle strength

Intervention type: OTHER
Intervention: Respiratory function
Description: Respiratory function test evaluates the participants' pulmonary function and respiratory muscle strength
Study: NCT03695939

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: realSKIN (skin xenotransplant)
Description: 3+3 Dose-escalation Study Design; 2 dosage strengths will be utilized during this Phase 1/2 Trial; an expansion cohort (9 patients) receive the highest dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Cadaver Allograft
Description: HCA is used as a temporary wound dressing between debridement and definitive closure in many well-resourced contexts.
Study: NCT03601377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training away from threat
Description: Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (\< or \>) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training towards threat
Description: Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (\< or \>) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dot-probe task: Pairs of stimuli, angry - neutral face or neutral - neutral faces of the same actor (20 different individuals;10 male, 10 female) are presented horizontally in the centre of the screen (160 trials; 120 angry-neutral and 40 neutral-neutral). Each trial begins with a fixation cross (500 ms), on which the participants are instructed to focus their gaze. After that a pair of faces follows which is presented on the screen for 500ms. After the faces presentation a small visual probe (\< or \>) appears at the same place of one of the two faces. Participants have to determine which symbol appeared by clicking right or left on the mouse as quickly as possible. The target probe remains on the screen until there is a response, which starts a new trial.
Study: NCT04723914

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dual target CAR-T cell therapy
Description: CD19/CD20 dual target CAR-T cell therapy
Study: NCT03237572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (200 mg)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU)
Description: Ablation will target 50% of the tumor, up to 3 cubic centimeters

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU)
Description: Ablation will target 50% of the tumor, up to 3 cubic centimeters
Study: NCT02754349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SphygmoCor version 7, AtCor Medical, Sydney, Australia
Description: Pulse wave velocity, augmentation index and central blood pressure measurement with applanation tonometry before and after electrical cardioversion
Study: NCT00480402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg of Progesterone
Description: Administration of 200 mg of Progesterone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg Progesterone
Description: Administration of 400 mg Progesterone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administration of a Placebo
Study: NCT03133013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SLEEPSCOPE
Description: Brainwave measurement device which is connected to the participant by an electrode attached to the forehead and another electrode behind one ear
Study: NCT01924598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS to nucleus accumbens/anterior limb of internal capsule
Description: deep brain stimulation followed by 12 month post switch on followup
Study: NCT01294813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography (EIT)
Description: EIT measurements of 1-2 minutes are performed in patients who routinely undergo bronchoscopy (during 1.5 hours) before, directly after and 10, 30, 60 minutes after bronchoscopy. Therefore the rubber belt including 16 integrated electrographic electrodes is placed around the patient´s chest and connected with an EIT device. EIT data are generated by application of a small alternating current of 5mA and 50kHz and are stored and analyzed offline on a personal computer. Pseudonomyzed EIT data are evaluated descriptively.